Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 199Leukemia, Lymphocytic, Chronic, B-Cell 169Leukemia 165Myelodysplastic Syndromes 162Precursor Cell Lymphoblastic Leukemia-Lymphoma 151Lymphoma, Non-Hodgkin 129Lymphoma 120Multiple Myeloma 112Hodgkin Disease 110Lymphoma, Follicular 97Lymphoma, Mantle-Cell 95Lymphoma, Large B-Cell, Diffuse 87Lymphoma, B-Cell, Marginal Zone 79Myeloproliferative Disorders 77Burkitt Lymphoma 75Congenital Abnormalities 73Leukemia, Myelogenous, Chronic, BCR-ABL Positive 67Leukemia, Myelomonocytic, Chronic 66Leukemia, Myeloid, Chronic-Phase 64Leukemia, Myeloid, Accelerated Phase 62Recurrence 57Lymphoma, Large-Cell, Immunoblastic 55Waldenstrom Macroglobulinemia 50Anemia, Refractory, with Excess of Blasts 50Primary Myelofibrosis 48Neoplasms, Plasma Cell 47Blast Crisis 47Hematologic Neoplasms 40Leukemia, Prolymphocytic 37Dendritic Cell Sarcoma, Interdigitating 37

Interventions

pembrolizumab 2fludarabine 2Radiosurgery 2Paclitaxel 2Gemcitabine 2Cyclophosphamide 2Cisplatin 2Carboplatin 2Anthropogenic Effects 2venetoclax 1umbralisib 1ublituximab 1regorafenib 1pazopanib 1niraparib 1neratinib 1lutetium Lu 177 dotatate 1ibrutinib 1grapiprant 1fludarabine phosphate 1famitinib 1encorafenib 1copanlisib 1cemiplimab 1capivasertib 1camrelizumab 1brigatinib 1binimetinib 1axicabtagene ciloleucel 1avelumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Disease Progression × fludarabine phosphate × Clear all
NCT04205838 2026-02-27

Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell Lymphoma

Jonsson Comprehensive Cancer Center

Phase 2 Terminated
23 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡